Oxygen carriers ("blood substitutes").
Copyright policy )Oxygen carriers ("blood substitutes").
(1) A number of oxygen carriers, or "blood substitutes", are undergoing clinical trials. One product (Hemopure(R)) was recently licensed for use in South Africa. Another, (Hemolink(tm) may soon be approved for marketing in Canada. (2) Most trials of oxygen carriers have focused on their use in surgery, primarily as a way to minimize the need for allogeneic blood transfusion. (3) The benefits of these products in comparison with other blood conservation technologies and with allogeneic blood transfusion must be determined. (4) The safety and cost-effectiveness of these products, and the patient populations that would benefit most from their use require further study.
Canada, Clinical Trials as Topic, Fluorocarbons, Technology Assessment, Biomedical, Drug Costs, Hemoglobins, South Africa, Raffinose, Blood Substitutes, Humans, Drug Approval
Canada, Clinical Trials as Topic, Fluorocarbons, Technology Assessment, Biomedical, Drug Costs, Hemoglobins, South Africa, Raffinose, Blood Substitutes, Humans, Drug Approval
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!